Related references
Note: Only part of the references are listed.Biology and significance of alpha-fetoprotein in hepatocellular carcinoma
Peter R. Galle et al.
LIVER INTERNATIONAL (2019)
Post-treatment alpha-fetoprotein response predicts prognosis of patients with hepatocellular carcinoma A meta-analysis
Chao He et al.
MEDICINE (2019)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Radiofrequency Ablation of Hepatocellular Carcinoma as First-Line Treatment: Long-term Results and Prognostic Factors in 162 Patients with Cirrhosis
Dong Ho Lee et al.
RADIOLOGY (2014)
Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib
Takahide Nakazawa et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2013)
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Philip J. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
Ann-Lii Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
Hashem B. El-Serag
GASTROENTEROLOGY (2012)
Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines
Kenichi Takayasu et al.
JOURNAL OF HEPATOLOGY (2012)
Radiofrequency Ablation of Hepatocellular Carcinoma: Long-term Results and Prognostic Factors in 235 Western Patients with Cirrhosis
Gisele N'Kontchou et al.
HEPATOLOGY (2009)
Immortal time bias in pharmacoepidemiology
Samy Suissa
AMERICAN JOURNAL OF EPIDEMIOLOGY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Share Paper
